ArticleBreast cancer research : BCR2020

Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.

Kyung-Min Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.